John De Vos

BioNTech co-founders to exit company and start a new one BioNTech founders Sahin and Türeci to depart by year-end to start new mRNA company; BioNTech to focus on late-stage pipeline and take minority stake in new venture.

BioNTech co-founders to exit company and start a new one
buff.ly/y8vK8nh

Des médecins remettent en cause l'impartialité de la HAS, après un mauvais avis rendu sur une thérapie génique Une thérapie génique, issue d'une découverte française, pouvant soigner deux maladies du sang, a été stoppée en France après un avis défavorable de la Haute autorité de santé (HAS), révèle France…

Pas de CASGEVY en France (CRISPR/Cas9 pour la Bêta Thalassémie et la Drépanocytose)?

Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans Chinese firm Belief BioMed launches $350K hemophilia B gene therapy, challenging $3.5M Hemgenix by CSL Behring/uniQure, as China leads global race for cheaper gene therapies.

China approved a gene therapy at 1/10 the price of its U.S. rival. China is poised to rapidly disrupt the gene and cell therapy field.

buff.ly/CfZDNgS

First-of-a-kind stem-cell therapies set for approval in Japan Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

Nature comment: two first #iPSCells medicines got conditional approval after treating only 7–8 patients

Smart acceleration or risky precedent?

buff.ly/2PgcKWj

📣 📣 📣 World first!!

Japan’s health ministry has granted a provisional 7-year approval for the commercialization of two regenerative medicine products derived from #iPSCells, aimed at treating ischemic cardiomyopathy and Parkinson’s disease.
buff.ly/nAKKmib

Merci à Nicolas Henin pour ce fil qui vous explique comment changer de Blue en Eurosky

It’s a really weird time in tech. You’re excited at the idea that AI coding agents are making people 20% - 200% more productive but also know the bean counters are asking if that means they can get away with 2%-20% layoffs.

This is also a very good reason to completely abandon American big tech and their utterly corrupt leaders who only want to enrich themselves.

This article gives an overview of 20 European Alternatives to Major US Technology Services.

Europe has had more than enough of this disgusting mafia gang!

Severus detects somatic structural variation and complex rearrangements in cancer genomes using long-read sequencing - Nature Biotechnology Complex structural variations and rearrangements in cancer are identified using long-read sequencing.

Complex structural variations and rearrangements in cancer are identified using long-read sequencing go.nature.com/3R334eH
rdcu.be/e5kOO

AI agents have caused a sea change in programming, going from hype to reality last December.

That Claude takes English instructions to build apps, configure settings, and self-correct errors is magical to behold. It’s easy to dismiss without trying the latest models, but code is effectively free.

Failing to find a buyer, BioMarin pulls Roctavian in gene therapy's biggest disappointment For all its blockbuster hopes and high-profile status in the gene therapy field, Roctavian's commercial saga has ended.

Wow. That’s really heartbreaking.

Failing to find a buyer, BioMarin pulls Roctavian in gene therapy's biggest disappointment

Exclusive: First test of gene therapy for rare form of autism is underway Two years ago, a small biotech startup got permission to test a gene therapy for a rare and disabling form of autism. The plan: Deliver a gene that’s vital for ...

First test of gene therapy for a rare form of autism is underway.

Jaguar Gene Therapy dosed the first child a year ago and has since treated four more, all between the ages of 2 and 4, diagnosed with Phelan-McDermid syndrome (SHANK3 mutations).

buff.ly/UooaRDV

Gilead to acquire cell therapy partner Arcellx for $7.8B Gilead Sciences acquires Arcellx for $7.8B, gaining full control of multiple myeloma CAR-T therapy anito-cel ahead of potential FDA approval and launch this year.

Gilead to acquire cell therapy partner Arcellx for $7.8B.
At the center of the buyout is anito-cel, which is the multiple myeloma CAR-T cell therapy that Gilead and Arcellx are already developing together. The treatment is expected to be a safer option.

😕

The strongest version of this illusion I’ve seen! Absolute head-wrecker!

Review: Viral genome editing methods and applications in the CRISPR era
journals.asm.org/doi/10.1128/...

A first-in-human #GeneTherapy clinical trial is being launched to evaluate partial cellular reprogramming of the eye using AAV delivery of OCT4, SOX2, & KLF4 under doxycycline control, targeting two forms of age-related vision loss. Based on the work of David Sinclair (Harvard).

buff.ly/uV4kbgU

If Epstein is Trending, Why Isn’t +1.7°C? The news cycle has become a hall of mirrors: Epstein, Trumpism, war, outrage, retribution. A thousand scandals designed to keep us anxious, tribal, and tired. We have to hold multiple truths at once: ...

"This is the hard truth I want to land: climate does not care what’s trending. It’s not interested in Jeffrey Epstein, Gaza, or Greenland. There is no algorithmic mercy. Physics is physics, and it is getting more abrupt."
#climatecrisis #ElNino #auspol www.lyrebirddreaming.com/post/we-are-...

a close up of a sunflower with a red center ALT: a close up of a sunflower with a red center

D. Mionet #Geopolitis manque terriblement 😭 si quelqu'un a des nouvelles parmi vous je suis preneur...

FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases As the first CAR-T treatment for an autoimmune disease dr | As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDA’s Vinay Prasad, M.D., and colleagues have signaled a willi...

FDA reflections on #CARTCells therapies and autoimmunity: the key challenge is finding the match between the right product and the right indication.

www.fiercebiotech.com/biotech/fda-...

Nature and Science journalists denied entry to event featuring NIH Director

😂

I love this!

Biomaterial-minimalistic photoactivated bioprinting of cell-dense tissues We developed a bioprinting strategy that turns living cells into cell-only bioinks, enabling light-based 3D bioprinting of tissues at native, ultrahigh cell densities (up to ∼109 cells mL−1) to rapidl...

A scaffold-free bioprinting approach achieves physiological cell densities, and is used to print in vitro models of heart and liver structures, and neural circuits #NBThighlight www.cell.com/cell/fulltex...

AI companies will fail. We can salvage something from the wreckage | Cory Doctorow AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots

[AI companies will fail. We can salvage something from the wreckage | AI (artificial intelligence) |The Guardian]

“AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots“

www.theguardian.com/us-news/ng-i...

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia | NEJM In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is d...

Another major triumph for a refractory autoimmune disease—hemolytic anemia—through engineered T cells
@nejm.org
nejm.org/doi/full/10....

Ludovic Vallier, Stem Cell Reports Associate Editor, is attending Biotherapy Days 2026 in Toulouse, France 28-30 January 2026. Connect with him to discuss whether your research is a fit for publishing in Stem Cell Reports!

Bar graph showing global ocean heat content change in the upper 2000 m from the late 1950s through 2025. There is a long-term warming in the time series, which is using IAP/CAS data.

2025 was the hottest year on record for ocean heat content. Unfortunately, we now say this every year. 🥹

"In addition to setting a new record in 2025, the global
ocean continues to show sustained and intensified warming."

+ #OpenAccess Study: doi.org/10.1007/s003...
+ Data: www.ocean.iap.ac.cn

Other data regarding #CARTCell treatments in France. Interesting!

Source : buff.ly/k3Z9kDv

Number of #CARTCell treatments in France : rapidly increasing.

Source : buff.ly/k3Z9kDv